-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
From February 20, 2022 to February 26, 2022, 16 new varieties (deemed) passed the consistency evaluation, of which 4 were the first in the country
.
The four varieties are Compound Amino Acid (15) Dipeptide (2) Injection from Kelun Pharmaceuticals, Calcitriol Capsules from Chongqing Hemony, Calcium Gluconate Injection from Chengdu Beite, and Puyuan Medicine from Wuhan industry's ursodeoxycholic acid tablets
.
On February 24, the website of the State Drug Administration showed that the calcium gluconate injection of Chengdu Beite Pharmaceuticals passed the consistency evaluation of generic drugs, which was the first domestic evaluation
.
At present, a total of 50 domestic companies have the production approval for calcium gluconate injection, but only 5 companies have submitted supplementary applications for the consistency evaluation of this product, including Hebei Tiancheng Pharmaceutical, Chengdu Bite Pharmaceutical, China Resources Shuanghe Limin, Jiangsu Huayang Pharmaceutical, Yangzhou Zhongbao Pharmaceutical
.
Calcium gluconate injection is a commonly used intravenous calcium supplementation drug in clinical practice.
It is suitable for the treatment of calcium deficiency, acute hypocalcemia, alkalosis and tetany caused by hypoparathyroidism
.
Data shows that in 2020, the sales of terminal calcium gluconate injection in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan; in the first half of 2021, its sales increased year-on-year.
26.
20%, more than 300 million yuan
.
On February 24, the website of the State Drug Administration showed that the ursodeoxycholic acid tablets of Wuhan Puyuan Pharmaceutical had been over-reviewed
.
Ursodeoxycholic acid is a gallstone-dissolving drug, suitable for the treatment of: steroid gallstones—must be X-ray penetrable, and gallbladder contractile function must be normal; cholestatic liver disease (eg: primary biliary cirrhosis); bile reflux gastritis
.
The data shows that the sales of ursodeoxycholic acid in domestic sample hospitals in 2020 will be 552 million yuan, and the first three quarters of 2021 will increase by 19.
89% year-on-year to 477 million yuan.
The importer Dr.
falk (Germany) occupies 85% of the market share of this product
.
On February 21, the website of the State Drug Administration showed that Sichuan Kelun Pharmaceutical's compound amino acid (15) dipeptide (2) injection was approved and reviewed as a supplementary application, and it was the first company to review the product..
At present, there are 4 companies with production approval for this product
.
Compound Amino Acid (15) Dipeptide (2) Injection is suitable for patients who cannot be given oral or enteral nutritional supplements, and those whose nutritional needs cannot be met by these means, especially for patients with moderate to severe catabolic conditions
.
The data shows that the terminal sales of compound amino acid (15) dipeptide (2) injection in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) in 2020 are nearly 500 million yuan.
Year-on-year growth of more than 10% in the first half of 2021
.
On February 21, the website of the State Drug Administration showed that Chongqing Hemony's calcitriol capsules had been approved
.
In China, only Chongqing Hemony submitted a supplementary application for the consistency evaluation of calcitriol capsules, which was accepted by CDE in May 2021, and has been successfully approved for evaluation in less than a year, making it the first company in China
.
Calcitriol is an endogenous drug developed by Roche for the treatment of osteoporosis
.
According to the data, the sales of calcitriol in domestic sample hospitals in 2020 increased by 2.
34% year-on-year to 604 million yuan; the sales in the first three quarters of 2021 were 487 million yuan, and the sales growth increased steadily
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
The four varieties are Compound Amino Acid (15) Dipeptide (2) Injection from Kelun Pharmaceuticals, Calcitriol Capsules from Chongqing Hemony, Calcium Gluconate Injection from Chengdu Beite, and Puyuan Medicine from Wuhan industry's ursodeoxycholic acid tablets
.
On February 24, the website of the State Drug Administration showed that the calcium gluconate injection of Chengdu Beite Pharmaceuticals passed the consistency evaluation of generic drugs, which was the first domestic evaluation
.
At present, a total of 50 domestic companies have the production approval for calcium gluconate injection, but only 5 companies have submitted supplementary applications for the consistency evaluation of this product, including Hebei Tiancheng Pharmaceutical, Chengdu Bite Pharmaceutical, China Resources Shuanghe Limin, Jiangsu Huayang Pharmaceutical, Yangzhou Zhongbao Pharmaceutical
.
Calcium gluconate injection is a commonly used intravenous calcium supplementation drug in clinical practice.
It is suitable for the treatment of calcium deficiency, acute hypocalcemia, alkalosis and tetany caused by hypoparathyroidism
.
Data shows that in 2020, the sales of terminal calcium gluconate injection in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) exceeded 600 million yuan; in the first half of 2021, its sales increased year-on-year.
26.
20%, more than 300 million yuan
.
On February 24, the website of the State Drug Administration showed that the ursodeoxycholic acid tablets of Wuhan Puyuan Pharmaceutical had been over-reviewed
.
Ursodeoxycholic acid is a gallstone-dissolving drug, suitable for the treatment of: steroid gallstones—must be X-ray penetrable, and gallbladder contractile function must be normal; cholestatic liver disease (eg: primary biliary cirrhosis); bile reflux gastritis
.
The data shows that the sales of ursodeoxycholic acid in domestic sample hospitals in 2020 will be 552 million yuan, and the first three quarters of 2021 will increase by 19.
89% year-on-year to 477 million yuan.
The importer Dr.
falk (Germany) occupies 85% of the market share of this product
.
On February 21, the website of the State Drug Administration showed that Sichuan Kelun Pharmaceutical's compound amino acid (15) dipeptide (2) injection was approved and reviewed as a supplementary application, and it was the first company to review the product..
At present, there are 4 companies with production approval for this product
.
Compound Amino Acid (15) Dipeptide (2) Injection is suitable for patients who cannot be given oral or enteral nutritional supplements, and those whose nutritional needs cannot be met by these means, especially for patients with moderate to severe catabolic conditions
.
The data shows that the terminal sales of compound amino acid (15) dipeptide (2) injection in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) in 2020 are nearly 500 million yuan.
Year-on-year growth of more than 10% in the first half of 2021
.
On February 21, the website of the State Drug Administration showed that Chongqing Hemony's calcitriol capsules had been approved
.
In China, only Chongqing Hemony submitted a supplementary application for the consistency evaluation of calcitriol capsules, which was accepted by CDE in May 2021, and has been successfully approved for evaluation in less than a year, making it the first company in China
.
Calcitriol is an endogenous drug developed by Roche for the treatment of osteoporosis
.
According to the data, the sales of calcitriol in domestic sample hospitals in 2020 increased by 2.
34% year-on-year to 604 million yuan; the sales in the first three quarters of 2021 were 487 million yuan, and the sales growth increased steadily
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
